Egalet's Guardian Technology receives US patent
21 February 2018 | News
Egalet Announces Issuance of New U.S. Patent for Guardian™ Technology
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, has received a US patent for its proprietary Guardian Technology.
The patent covers the Guardian Technology two-component tablet architecture which provides precise drug delivery and can confer abuse-deterrent properties.
The United States Patent and Trademark Office (USPTO) have issued patent number 9,884,029 covering Egalet-002. The patent offers protection through March 2024.
Egalet has been granted a total of 20 US patents and 59 patents outside of the US that cover Guardian Technology and its product candidate
